People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.